Any current/future new fundraising through debt or equity?

No specific mention of any current or planned fundraising through debt or equity in the transcript. The company is focusing its CAPEX on cost-cutting, maintenance, R&D overhaul, and expansion of styrene butadiene latex capacity. Board and senior management are cautious about new investments (e.g., in NBR), preferring to wait for better market clarity and margins before committing to new projects. They plan to announce details of R&D investment and styrene butadiene latex capacity expansion in the next 3 to 6 months. No direct indication of raising funds via debt or equity for these pro

Any current/future capex/capital investment/strategic investment?

Current approved CAPEX focuses on projects to cut operating costs and maintenance. Planning a complete overhaul and consolidation of R&D centers into a new building at Taloja, investing in R&D team growth. Additional upcoming investment in styrene butadiene latex capacity expansion expected to be utilized by end of next year; project lead time about one year. No immediate plans for NBR capacity expansion due to current low margins and market conditions; watching the space with potential decision in next year or so. Considering possible use of existing excess capacity and plant space for styren

Future growth expectations in sales/revenue/volumes?

Q1 FY25 showed a strong volume growth of approximately 14% year-on-year. Revenue growth for the same period was around 21%. The company aims to increase volume capacity, capacity utilization, and improve margins. Export sales, constituting about 30% of total sales, also saw growth despite logistical challenges. Capacity utilization in the Valia plant (gloves project) is expected to rise from 50% to around 65% in the next 1-2 quarters. Taloja plant is operating at about 70% capacity utilization; expected to reach full utilization in 1 to 1.5 years. Anticipates gradual margin improvement as glov

Future growth expectations in earnings/operating earnings/profits/EPS?

The company achieved a 14% YoY volume growth and 21% revenue growth in Q1 FY25, signaling strong demand. Management plans to focus on increasing volume capacity, capacity utilization, and improving margins going forward. The gloves segment volume is growing, but margins are currently muted; however, margins are expected to improve as the glove industry recovers. Additional CAPEX is planned for R&D and expanding styrene butadiene latex capacity by end of next year, supporting future growth. Margins in core non-glove segments are expected to improve from current 10-15% range to 13-17% over the n

Apcotex IndustriQ1 FY25Industrial Products

Apcotex Industri Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹593P/E: 19.3Market Cap: ₹3.1K CrSector: Industrial Products

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Q1 FY25 showed a strong volume growth of approximately 14% year-on-year.
Revenue growth for the same period was around 21%.
The company aims to increase volume capacity, capacity utilization, and improve margins.
Export sales, constituting about 30% of total sales, also saw growth despite logistical challenges.
Capacity utilization in the Valia plant (gloves project) is expected to rise from 50% to around 65% in the next 1-2 quarters.
Taloja plant is operating at about 70% capacity utilization; expected to reach full utilization in 1 to 1.5 years.
Anticipates gradual margin improvement as glove industry margins recover and utilization rates increase.
Plans for CAPEX include investments in R&D consolidation and expansion of styrene butadiene latex capacity, signaling confidence in future growth.
Overall volume and revenue growth are expected to continue, with better margin traction over the next few quarters.

Margin guidance

Category 3

The company achieved a 14% YoY volume growth and 21% revenue growth in Q1 FY25, signaling strong demand.
Management plans to focus on increasing volume capacity, capacity utilization, and improving margins going forward.
The gloves segment volume is growing, but margins are currently muted; however, margins are expected to improve as the glove industry recovers.
Additional CAPEX is planned for R&D and expanding styrene butadiene latex capacity by end of next year, supporting future growth.
Margins in core non-glove segments are expected to improve from current 10-15% range to 13-17% over the next 4-5 years.
Export growth remains strong (+12% YoY), though short-term logistical challenges exist.
Overall, the company expects steady volume and margin expansion leading to improved profitability and EPS in upcoming quarters.

See what Apcotex Industri management said on margin guidance — free account, 30 seconds.

Fundraise plans

No specific mention of any current or planned fundraising through debt or equity in the transcript.
The company is focusing its CAPEX on cost-cutting, maintenance, R&D overhaul, and expansion of styrene butadiene latex capacity.
Board and senior management are cautious about new investments (e.g., in NBR), preferring to wait for better market clarity and margins before committing to new projects.
They plan to announce details of R&D investment and styrene butadiene latex capacity expansion in the next 3 to 6 months.
No direct indication of raising funds via debt or equity for these projects; focus appears to be on internal cash flow and prudent capital allocation.

Order book

The document does not provide specific details on the current or expected order book or pending orders for Apcotex Industries. There is no mention of the volume or value of pending orders or a backlog segment in the provided earnings call transcript. The focus of the discussion is primarily on volume growth, capacity utilization, product mix, margin trends, and challenges in the glove and latex segments. If you need detailed order book information, it may not be available in this particular transcript.

See what Apcotex Industri management said on order book — free account, 30 seconds.

Capex plans

Yes

Current approved CAPEX focuses on projects to cut operating costs and maintenance.
Planning a complete overhaul and consolidation of R&D centers into a new building at Taloja, investing in R&D team growth.
Additional upcoming investment in styrene butadiene latex capacity expansion expected to be utilized by end of next year; project lead time about one year.
No immediate plans for NBR capacity expansion due to current low margins and market conditions; watching the space with potential decision in next year or so.
Considering possible use of existing excess capacity and plant space for styrene butadiene and other latex products; decision expected in next 3 to 6 months.
Overall, strategic CAPEX investments aim to improve margins, increase capacity utilization, and enhance product development.

Track Apcotex Industri — get its next earnings analysis in your feed

How does Apcotex Industri rank vs peers in Industrial Products?

Pro feature

ThisApcotex Industri

Rev 3Mar 3

See where Apcotex Industri sits in Industrial ProductsSee which companies these are, and every other name in the sector.Open rankings

How does Apcotex Industri rank in Industrial Products?

Compare Apcotex Industri against every Industrial Products company (Q1 FY25) on revenue, margins and earnings-call signals.

View Industrial Products leaderboard →

What Apcotex Industri's management said in earlier quarters

Others in Industrial Products this season

Monolithisch India Ltd (Q2 FY27)
Combined additional capacity: 3 lakh MT per annum; total capex approximately INR 45 crores. Key concall takeaways from Monolithisch India Ltd's Q2 FY27…
Systematic Industries Ltd (Q1 FY27)
Year-on-Year (YoY) Growth for Q4 Net Sales:** 6.0% . Key concall takeaways from Systematic Industries Ltd's Q1 FY27 earnings call — and how it ranks against…
Graphite India Ltd (Q3 FY24)
690 crore, down 1.6% y-o-y (Page 5, 9) . Key concall takeaways from Graphite India Ltd's Q3 FY24 earnings call — and how it ranks against sector peers.
Graphite India Ltd (Q4 FY24)
720 Cr, down 11.7% y-o-y (Page 4, 9) . Key concall takeaways from Graphite India Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.

Compare:vs Polycab India Ltd vs Welspun Corp Ltd vs APL Apollo Tubes

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Apcotex Industri Q1 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Apcotex Industri rank in Industrial Products?

Continue your research

What Apcotex Industri's management said in earlier quarters

Others in Industrial Products this season